Zacks Research Has Bullish Outlook for Cencora Q3 Earnings

Cencora, Inc. (NYSE:COR - Free Report) - Stock analysts at Zacks Research raised their Q3 2025 EPS estimates for shares of Cencora in a research report issued on Wednesday, February 26th. Zacks Research analyst I. Bandyopadhyay now expects that the company will post earnings per share of $3.74 for the quarter, up from their previous estimate of $3.57. The consensus estimate for Cencora's current full-year earnings is $15.37 per share. Zacks Research also issued estimates for Cencora's Q1 2026 earnings at $3.93 EPS, Q2 2026 earnings at $4.45 EPS, FY2026 earnings at $16.65 EPS, Q1 2027 earnings at $4.21 EPS and FY2027 earnings at $18.07 EPS.

Several other brokerages have also issued reports on COR. Robert W. Baird raised their price target on shares of Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a research note on Thursday, November 7th. JPMorgan Chase & Co. raised their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a report on Friday, January 24th. Wells Fargo & Company raised their price objective on shares of Cencora from $237.00 to $251.00 and gave the stock an "equal weight" rating in a report on Wednesday, January 29th. Barclays raised their price objective on shares of Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. Finally, Evercore ISI raised their price objective on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $277.90.

Cencora Stock Performance

Shares of COR stock traded up $1.68 during trading hours on Friday, hitting $255.22. 1,367,959 shares of the company were exchanged, compared to its average volume of 1,500,199. The firm has a fifty day simple moving average of $241.71 and a 200 day simple moving average of $237.85. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. Cencora has a 52-week low of $214.77 and a 52-week high of $262.26. The stock has a market capitalization of $49.49 billion, a price-to-earnings ratio of 36.30, a P/E/G ratio of 1.31 and a beta of 0.49.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. JFS Wealth Advisors LLC lifted its holdings in shares of Cencora by 63.0% during the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock worth $27,000 after acquiring an additional 46 shares during the last quarter. Banque Transatlantique SA bought a new stake in shares of Cencora during the 4th quarter worth $29,000. SBI Securities Co. Ltd. bought a new stake in shares of Cencora during the 4th quarter worth $30,000. Kentucky Trust Co bought a new stake in shares of Cencora during the 4th quarter worth $33,000. Finally, Householder Group Estate & Retirement Specialist LLC lifted its holdings in shares of Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after acquiring an additional 69 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the firm's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares of the company's stock, valued at $4,649,648.88. This trade represents a 7.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 10.80% of the company's stock.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be issued a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.86%. The ex-dividend date is Friday, February 14th. Cencora's payout ratio is 31.29%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.